Showing results (471-480 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|February 1, 1997
Studies on the discontinuous N-oxidation of trimethylamine among Jordanian, Ecuadorian and New Guinean populationsS C Mitchell, A Q Zhang, T Barrett, et al.Pharmacogenetics|February 1, 1997
Polymorphic N-acetyltransferase (NAT2) genotyping of EmiratisN M Woolhouse, M M Qureshi, S M Bastaki, et al.Pharmacogenetics|October 1, 1996
Selective expression of CYP3A5 and not CYP3A4 in human bloodS K Janardan, K S Lown, P Schmiedlin-Ren, et al.Pharmacogenetics|August 1, 1996
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanismsE Y Krynetski, H L Tai, C R Yates, et al.Pharmacogenetics|August 1, 1996
CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit populationM Jurima-Romet, J A Goldstein, M LeBelle, et al.Pharmacogenetics|February 1, 1996
Genetic factors and risk of agranulocytosis from metamizolV Vlahov, N Bacracheva, D Tontcheva, et al.Pharmacogenetics|February 1, 1996
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitorM VandenBranden, B J Ring, S N Binkley, et al.Pharmacogenetics|October 1, 1995
Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activityD L Eaton, E P Gallagher, T K Bammler, et al.Pharmacogenetics|October 1, 1995
Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepamM Patel, B K Tang, D M Grant, et al.Pharmacogenetics|October 1, 1995
A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotypeD Marez, N Sabbagh, M Legrand, et al.Pageof 83